The basis for the vestibular complaint in dizzy patients should be viewed as having an etiology rather than a description of its clinical presentation. Effective treatment of vestibular disorders is based on the stabilization of the vestibular abnormality, to allow for central vestibular compensation. While not all of the etiologies for dizziness have been described, there are effective etiologic treatments available. These fit into categories of neurotransmitters, blood sugar and blood fat control, hormones, minerals, and treatments for autoimmune dizziness.
Get full access to this article
View all access options for this article.
References
1.
NorellIStahleJ. Treatment of Meniere's disease with hydrochlorothiazide. Acta Otolaryngol1962; 54:447–56.
2.
BrackmannDENissenRL. Meniere's disease: Results of treatment with the endolymphatic subarachnoid shunt compared with endolymphatic mastoid shunt. Am J Otol1987; 8:275–82.
3.
SnowJBKimmelmanCP. Assessment of surgical procedures for Meniere's disease. Laryngoscope1979; 89:737–47.
4.
NorrisCH. Application of streptomycin to the lateral semicircular canal. Trans Am Otol Soc1988; 75:84–8.
5.
BlackFOSandoIHildyardVHHemenwayWG. Bilateral multiple otosclerotic foci and endolymphatic hydrops. Ann Otol Rhinol Laryngol1969; 78:1062.
6.
PowersWH. Metabolic aspects of Meniere's disease. Laryngoscope1972; 82:1716–25.
7.
PowersWH. Allergic factors in Meniere's disease. Trans Am Acad Ophthalmol Otolaryngol1973; 77:22–9.
8.
SchuknechtHF. Delayed endolymphatic hydrops. Ann Otol Rhinol Laryngol1978; 87:743–8.
9.
SpencerJT. Hyperlipoproteinemia, hyperinsulinism, and Meniere's disease. South Med J1981; 74:1194.
10.
YooTJStuartJMKangAHTownesASTomodaKDixitS. Type II collagen autoimmunity in otosclerosis and Meniere's disease. Science1982; 217:1153–5.
11.
RauchSDMerchantSNThedingerBD. Meniere's syndrome and endolymphatic hydrops. Ann Otol Rhinol Laryngol1989; 98:873–83.
12.
GuthPSMelamedB. Neurotransmission in the auditory system: A primer for pharmacologists. Ann Rev Pharmacol Toxicol1982; 22:383–412.
GrowdonJHWurtmanRJ. Treatment of brain disease with dietary precursors of neurotransmitters. Ann Intern Med1977; 86:337–9.
15.
WoodCDGraybielA. A theory of motion sickness based on pharmacological reactions. Clin Pharmacol Ther1970; 11:621–9.
16.
GodfreyDARossCD. Enzymes of acetylcholine metabolism in the rat cochlea. Ann Otol Rhinol Laryngol1985; 94:409–14.
17.
GoldmanHB. Metabolic causes of fluctuant hearing loss. Otolaryngol Clin North Am1975; 8:369–74.
18.
BretlauPSalomonGJohnsenNJ. Otospongiosis and sodium fluoride: A clinical double-blind, placebo-controlled study on sodium fluoride treatment of otospongiosis. Am J Otol1989; 10:20–2.
19.
ShambaughGE. How and when to prescribe sodium fluoride. Am J Otol1989; 10:146–7.
20.
RichmondVL. Thirty years of fluoridation: A review. Am J Clin Nutr1985; 41:129–38.
21.
CausseJRRuielJBergesJBretlauPShambaughGEJCausseJB. Objective changes in trypsin, alpha 1 trypsin, and alpha 2 macroglobulin values as a result of sodium fluoride treatment in patients with otosclerosis. Am J Otol1985; 6:38–42.
22.
SandoIHemenwayWGMillerDBlackFO. Vestibular pathology in otosclerosis. Temporal bone histopathological report. Laryngoscope1974; 84:593–605.
23.
BrookesGB. Vitamin D deficiency and deafness: 1984 update. Am J Otol1985; 6:102–7.
24.
McCabeB. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol1979; 88:585–9.
25.
KanzakiJOuchiT. Steroid-responsive bilateral sensorineural hearing loss and immune complexes. Arch Otorhinolaryngol1983; 230:5–9.
26.
ShumakKHRockGA. Therapeutic plasma exchange. N Engl J Med1984; 310:762–71.
